Bose P et al. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 2020;34(9):2489-92. Abstract
Issa GC et al. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 2020;34(11):2914-24. Abstract
Jacoby MA et al. A pilot study of CPX-351 (Vyxeos©) for transplant eligible, higher risk patients with myelodysplastic syndrome. ASH 2021;Abstract 540.
Kim K et al. A phase II study of CPX-351 plus venetoclax in patients with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML). ASH 2021;Abstract 1275.
Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract
Lin TL et al. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: Phase 3 post hoc analyses. Blood Adv 2021;5(6):1719-28. Abstract
Masarova L et al. Clinical significance of bone marrow blast percentage in patients with myelofibrosis and the effect of ruxolitinib therapy. Clin Lymphoma Myeloma Leuk 2021;21(5):318-27.e6. Abstract
Masarova L et al. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 2020;126(19):4322-31. Abstract
Przespolewski AC et al. Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis. ASCO 2019;Abstract e18530.
Pullarkat V et al. Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML. ASCO 2021;Abstract 7026.
Pullarkat VA et al. Preliminary results by age group of treatment with CPX-351 plus venetoclax in adults with newly diagnosed AML: Subgroup analysis of the V-FAST phase 1b master trial. ASH 2021;Abstract 1268.
Rasche A et al. Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia. Br J Haematol 2021;194(5):927-31. Abstract
Rautenberg C et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J 2021;11(10):164. Abstract
Samra B et al. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 2020;10(5):47. Abstract
Singh A et al. Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Sci Rep 2021;11(1):23284. Abstract
Singh A et al. Evolving risk of therapy-related myelodysplastic syndromes and acute myeloid leukemia (tMDS/AML) following modern cancer therapies. ASCO 2020;Abstract 7516.
Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol 2022;171:103607. Abstract
Talati C et al. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res 2020;93:106367. Abstract
Uy GL et al. Phase 1b study of lower-dose CPX-351 plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy: Preliminary safety and efficacy results. ASH 2021;Abstract 2316.